Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Lars Wallentin(Uppsala University), Agneta Siegbahn(Uppsala University), Stefan James(Uppsala University), David Erlinge(Lund University), Kenneth J. Winters(Eli Lilly (United States)), Christoph Varenhorst, Oscar Ö. Braun(Lund University), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom))
Cited by 457
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k